Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alnylam Pharmaceuticals

454.38
-13.1700-2.82%
Post-market: 453.38-1.0000-0.22%19:52 EDT
Volume:1.08M
Turnover:493.92M
Market Cap:59.56B
PE:-184.42
High:469.81
Open:469.17
Low:454.20
Close:467.55
52wk High:469.81
52wk Low:205.87
Shares:131.08M
Float Shares:126.15M
Volume Ratio:0.96
T/O Rate:0.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4638
EPS(LYR):-2.1790
ROE:-257.82%
ROA:-2.63%
PB:237.68
PE(LYR):-208.52

Loading ...

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Baxter International (BAX)

TIPRANKS
·
Aug 01

U.S. RESEARCH ROUNDUP-Alnylam, Amazon, Appfolio

Reuters
·
Aug 01

Alnylam Pharmaceuticals Inc : Needham Raises Target Price to $478 From $377

THOMSON REUTERS
·
Aug 01

Chardan Capital Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

TIPRANKS
·
Aug 01

Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast

Benzinga
·
Aug 01

Alnylam Shares Rise After Strong 2Q, FDA Fast Track Designation

Dow Jones
·
Aug 01

Alnylam Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
Aug 01

Stock Track | Alnylam Pharmaceuticals Soars 13% as Q2 Earnings Crush Estimates, Guidance Raised

Stock Track
·
Jul 31

Alnylam Pharmaceuticals Shares Gain 13% After Co Raises FY Guidance, Q2 REV Beat

THOMSON REUTERS
·
Jul 31

Stock Track | Alnylam Pharmaceuticals Soars 6.53% Pre-market on Strong Q2 Earnings, Beating Estimates and Raising Guidance

Stock Track
·
Jul 31

Alnylam Pharmaceuticals Shares up 3% Premarket After Co Beats Q2 Net Product Revenue Estimates

THOMSON REUTERS
·
Jul 31

Alnylam Pharmaceuticals Q2 2025 Adj. EPS $0.34 Beats $(0.79) Estimate, Sales $773.689M Beat $638.548M Estimate

Benzinga
·
Jul 31

Alnylam Pharmaceuticals Reports Q2 2025 Results: Total Net Product Revenues Surge 64%, GAAP Net Loss Per Share Widens to $0.51, Non-GAAP EPS Down 41%

Reuters
·
Jul 31

Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress

THOMSON REUTERS
·
Jul 31

Alnylam Pharmaceuticals Inc Outlook FY Total Net Product Revenues $2,650 Million - $2,800 Million

THOMSON REUTERS
·
Jul 31

Alnylam Pharmaceuticals Q2 Basic EPS USD -0.51

THOMSON REUTERS
·
Jul 31

Alnylam Pharma (ALNY) Receives a Buy from Bernstein

TIPRANKS
·
Jul 30

Truist Securities Initiates Coverage on Alnylam Pharmaceuticals With Buy Rating, $385 Price Target

MT Newswires Live
·
Jul 21

Alnylam initiated with a Buy at Truist

TIPRANKS
·
Jul 21

Alnylam Pharmaceuticals Advances Pregnancy Safety Study for Patisiran-LNP

TIPRANKS
·
Jul 19